AIN-457 is a high-affinity fully human monoclonal antibody which inhibits interleukin- 17A (IL-17A). IL-17A is a pro-inflammatory cytokine secreted exclusively by activated T-cells. AIN-457 is intended for the treatment, or prevention of recurrence of non- infectious posterior segment uveitis in adults (including intermediate uveitis, posterior uveitis and vitritis). It is administered subcutaneously (SC) at 150mg once a week for the first three weeks, then every two weeks; or 300mg for the first three weeks, then monthly.
Ranibizumab as intravitreal injections is in clinical development for the treatment of diabetic retinopathy in both its proliferative and non-proliferative forms. Diabetic retinopathy, is a disease that affect the retinas and other parts of the inner eye. It is a chronic progressive condition of the retinal blood vessels due to prolonged raised blood glucose. When new blood vessels and scar tissue form on the retina causing bleeding within the eye and loss of vision, it is called proliferative diabetic retinopathy.